Congress Materials – Rheumatology Advanced Practice Providers (RhAPP 2024)
2024 Rheumatology Advanced Practice Providers | Sep 26-28 | Nashville, TN
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris, Jerry Bagel, Yu-Huei Huang, Andrew Pink, Stephen K. Tyring, Georgios Kokolakis, Amy M. DeLozier, Shu Li, Yaung-Kaung Shen, Anthony Todd, Takayuki Ota, Robert Bissonnette
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease, Ruizhi Zhao, Shannon Ferrante, Natalie J. Shiff, Pavithra Srinivas, Soumya D. Chakravarty, Jessica Walsh
Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
Dafna D. Gladman, Xenofon Baraliakos, Michael Starr, Roberto Ranza, Emmanouil Rampakakis, Natalie J. Shiff, Francois Nantel, Chenglong Han, Kate Callaway, Andrew Östör, Philip J. Mease
Efficacy and Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results of the GALAXI 2 & 3 Phase 3 Studies
Remo Panaccione, Silvio Danese, Brian Feagan, Geert D’Haens, Anita Afzali, Walter Reinisch, Julián Panés, David T. Rubin, Jane Andrews, Tadakazu Hisamatsu, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Kitty Yuen Yi Wan, Jenna Parrett, Jacqueline Yee, Bruce E. Sands
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie B. Lin, Anja Geldhof, Mauricio Rosas Ballina, Kate Callaway, Hetal Patel, Hewei Li
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Maintenance Study
David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky, Shadi Yarandi, Kuan-Hsiang G. Huang, Matthew Germinaro, Rebbecca Wilson, Hongyan Zhang, Jenna Parrett, Brian G. Feagan, Tadakazu Hisamatsu, Gary R. Lichtenstein, Brian Bressler, Laurent Peyrin-Biroulet, Bruce E. Sands, Axel Dignass
VISIBLE: Clearance and Symptom Improvement With Guselkumab at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
Linda Stein Gold, Jensen Yeung, Adrian O. Rodriguez, Jessica Vasquez, Olivia Choi, Katelyn Rowland, Theodore Alkousakis, Jenny Jeyarajah, Melissa Petrick, Javier Alonso-Llamazares, Stephen Tyring, April W. Armstrong
VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
Amy McMichael, Linda Stein Gold, Jennifer Soung, Chesahna Kindred, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Melissa Petrick, Candrice R. Heath, Tina Bhutani, Maxwell Sauder, Andrew Alexis
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.